NANOCURE

98 % of the human population is chronically infected by EBV. We propose an innovative platform for engineering
immunogenic bi-modular fusion proteins comprising a binding moiety and an EBV antigen to redirect an EBV preexisting
immune response towards a select cellular target. The aim is to develop efficient therapies triggering immune
mechanisms such as Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-mediated Cytotoxicity
(ADCC) and Antibody- Dependent Phagocytosis (ADP) to combat pathogens or treat pathologies such as cancer.

Applications :

• Treatment of cancers (such as
• B-cell lymphomas)
  Treatment of infectious diseases
  (such as malaria)

Competitive advantages :

• Applicable for 98 % of the population.
• Easy to produce as compared to current therapies such as
  monoclonal antibodies.
• Triggering of multiple immune effectors due to the recruitment of
  polyclonal antibodies.
• Allow efficacy improvement of current therapeutic antibodies.
• Versatile platform allowing large scale screening of binding moieties.
• Multiple applications (treatment of a large panel of diseases).

Keywords : Epstein-Barr Virus - Therapeutic molecular engineering - Antibody
fragments - Nanobodies - Immune effectors - Cellular cytotoxicity /
complement activation